TORONTO, Sept. 15, 2011 /CNW/ - Allegiance Equity Corporation (TSXV:ANQ.V) is pleased to announce that Nealanders will feature Allegiance's
proprietary CinGx revolutionary additive at the Supply Side West Event.
Nealanders International - a world-class supplier of ingredients and
additives in the food industry, the exclusive distributor of CinGx(TM)
in North America; will introduce CinGx at Supply Side West to be held
in Las Vegas October 10th - 14th.
Allegiance Equity Corporation recently developed CinGx, a unique product
to treat and prevent Type 3 Diabetes resulting from the impact of
Diabetes on brain function.
CinGx is a formula combining two extracts which act synergistically to
control glucose metabolism, improve cognitive function and
simultaneously minimize the risk of developing and treating CVD,
diabetes, dementia and Alzheimer's.
CinGx is a proprietary additive that enhances the value of any food,
beverage or nutritional supplement and can be combined with most other
ingredients. Products with CinGx to date include chocolate snacks,
yogurt and beverages.
Recent research discovered that the brain produces insulin and depriving
brain cells of insulin damages the cells, leading to memory loss,
dementia, and Alzheimer's Disease. The impact of high blood glucose
levels results in Type 3 Diabetes, also known as "brain diabetes."
CinGx(TM) will greatly benefit the rapidly increasing number of North
Americans diagnosed with diabetes, particularly Type 3 Diabetes.
"Diabetes is one of the clear metabolic risk factors for Alzheimer's
Disease (AD), perhaps through insulin signaling or secondary
cardiovascular effects," says Dr. Cantillon, American Board Certified
Neurologist and Psychiatrist. "After rosiglitazone and other failures,
there are no metabolic treatments in sight for AD that are effective
and/or do not have serious side effects. Therefore, insulin receptor
protein tyrosine kinase treatment for Type 3 Diabetes might represent a
new opportunity for long term safe prevention of Alzheimer's.
"We are extremely fortunate and grateful to have Nealanders as a
partner, you couldn't have asked for a better fit for Allegiance. They
are poised to market CinGx(TM) to their clients for placement in a
variety of foods and beverages", stated David Solomon, President of
Nealanders has completed regulatory documentation for compliance with
Health Canada and the FDA requirements to facilitate marketing CinGxTM to its clients. They have formulated foods and beverages in several
categories containing CinGxTM for presentation where Nealanders has established relationships and
rapport with key Marketing and Sales, as well as Product Development
"I am very excited about moving forward with this revolutionary new
additive, says Steve Owen, VP Sourcing, Product Development & GM -
Ontario. With the added value CinGx(TM) brings to our customers'
products and the important health benefits for consumers".
Nealanders is recognized as the leader in the manufacturing and
distribution of food ingredients, specializing in antioxidants, release
agents, dough conditioners and enrichment blends. Proudly Canadian,
Nealanders' Head Office is located in Mississauga, Ontario, with
facilities strategically located across North America providing their
customers with coast-to-coast coverage in both distribution and
technical sales. On the leading edge of emerging trends and a strategic
focus on wellness. Nealanders has extensive laboratory capabilities for
product development and full technical and regulatory support.
Nealanders embraces a customer focused mindset and value creation for
Allegiance targets billion dollar markets having clearly identified
product deficiencies and dissatisfied patients who suffer widespread
diseases and conditions including diabetes, cholesterol, Alzheimer`s
and Dementia and arthritis.
Allegiance's strategy utilizes leading-edge scientific technology to
create valuable, proprietary and effective natural treatments,
recognized as safe and effective by North American regulatory
authorities, at a fraction of the cost and time it takes to develop a
prescription drug. Allegiance then obtains patents and regulatory
Additional information relevant to the Company's activities, including
the Company's press releases can be found on SEDAR at www.sedar.com.
The TSX Venture Exchange has not reviewed and does not accept
responsibility FOR THE ADEQUACY OR ACCURACY FOR THIS PRESS RELEASE,
WHICH HAS BEEN PREPARED BY MANAGEMENT.
SOURCE Allegiance Equity Corporation
For further information:
Allegiance Equity Corporation
(416) 630 1221